Re: Farmas USA
A ver que opinais,para 2000 $ y dejarla que valla llegando sus ensayos
$.54 Archexin has FDA Orphan drug designation for five different cancer types, including renal cell carcinoma, glioblastoma, pancreatic, stomach and ovarian cancers.
Excellent results from Phase I, with fatigue being the only side effect.
http://www.rexahn.com/pdf/newwww/ASCO_Archexin%20Rexahn%202007.pdf
Based on the feedback that has been coming in, the Phase II results will be just as good, or even better. For me, as a doctor that has witnessed many dear friends succumb to this deadly disease, the potential this drug has is very overwhelming. As an investor, this stockprice is very attractive.